Our Leadership Team


Board Member
Executive Director, HOPU Investments

Tony Chang joined HOPU in 2014. Tony is an Executive Director of Healthcare investment team where he plays an integral role in building HOPU’s healthcare ecosystem, deal sourcing and execution, and post-investment value adds to portfolio companies. Tony led the investment of Ambrx Inc., a biopharmaceutical company headquartered in San Diego, I-Mab Biopharma, a China-based innovative drug company and Mevion Medical Systems, a proton therapy system company headquartered in Massachusetts. He also represents HOPU sitting on the board of Ambrx and Mevion.
Tony joined HOPU from China International Capital Corporation (CICC) Private Equity, a leading China-based private equity firm, where he was a Senior Associate. At CICC, he focused on investment in healthcare sector and participated in some successful investments in various areas including innovative drugs, medical devices & diagnostics and high-end services. His track record including: CHIVD, a leading provider of diagnostics reagents and systems, SonoScape (SZSE: 300633), a market leader of ultrasound diagnostic systems and transducers, BETTA Pharma (SZSE: 300558), a leading innovative biotech company focus on R&D of drugs for malignant tumors, diabetes, cardiovascular, and cerebrovascular diseases, and Amcare, one of the largest high-end full service provider of home care in China.
Prior to CICC, Tony worked for Roland Berger Strategy Consultants as the team leader where he managed more than 25 projects in 5 years in technology and healthcare sectors. His experience included corporate strategies, operation improvements, sales & marketing optimizations, corporate reorganization & governance and oversea business development.
Tony graduated from Tsinghua University with a B.S. and a M.S. in Electrical Engineering. Tony is also the charter-holder of Chartered Financial Analyst (CFA).